Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives

Cancer Genomics Proteomics. 2023 Dec;20(6suppl):637-645. doi: 10.21873/cgp.20412.

Abstract

Prostate cancer (PCa) is the second most common cancer in humans. Peptides have recently been used as targeted therapeutics in cancers, due to their extensive multi-functional applications. Two hypothalamic peptides, orexins A (OXA) and B (OXB) and their specific receptors, orexin receptor 1 (OX1R) and 2 (OX2R), orchestrate several biological processes in the central nervous system and peripheral organs. However, in addition to their role in physiological responses, orexins are involved in numerous inflammatory and/or neoplastic pathologies. The presence and expression of orexins in different cancer models, including prostate cancer, and their role in inducing pro- or anti-apoptotic responses in tumor cell lines, suggest that the orexinergic system might have potential therapeutic action or function as a diagnostic marker in PCa. In addition to the traditional animal models for studying human PCa, the canine model might also serve as an additional tool, due to its clinical similarities with human prostate cancer.

Keywords: Prostate cancer; hypocretins; orexin therapy; orexins; review.

Publication types

  • Review

MeSH terms

  • Animals
  • Dogs
  • Humans
  • Male
  • Orexin Receptors / metabolism
  • Orexins / metabolism
  • Prostatic Neoplasms* / drug therapy

Substances

  • Orexins
  • Orexin Receptors